
views
SkinBioTherapeutics – interims, Mr Market has it wrong. Strong Buy
SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2022 and the shares have been marked down in response. Mr Market has got it wrong and this is a Strong Buy.- By HotStockRockets
- 2023-03-30 08:35:37